Advanced Cervical Cancer - Pipeline Insight, 2024

This “Advanced Cervical Cancer - Pipeline Insight, 2024,” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Advanced Cervical Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Advanced Cervical Cancer Understanding

Advanced Cervical Cancer: Overview

Advanced cervical cancer means the cancer has spread from the cervix to another area of the body such as the lungs. Sometimes cancer is advanced when it is first diagnosed. Unfortunately advanced cancer can’t usually be cured. But treatment might control it, help symptoms, and improve your quality of life for a while. The most common places for cervical cancer to spread is to the lymph nodes, liver, lungs and bones. Treatment for advanced cervical cancer depends on the size of the cancer and where it is in the body. Chemotherapy can be used to treat advanced cervical cancer. Some women may have an operation called pelvic exenteration for cervical cancer that has come back within the pelvis.

Advanced Cervical Cancer - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Advanced Cervical Cancer pipeline landscape is provided which includes the disease overview and Advanced Cervical Cancer treatment guidelines. The assessment part of the report embraces, in depth Advanced Cervical Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Advanced Cervical Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Advanced Cervical Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Advanced Cervical Cancer.

Advanced Cervical Cancer Emerging Drugs Chapters

This segment of the Advanced Cervical Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Advanced Cervical Cancer Emerging Drugs

Imfinzi (durvalumab): AstraZenecaImfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumour’s immune-evading tactics and releasing the inhibition of immune responses. Imfinzi is the only approved immunotherapy in the curative-intent setting of unresectable, Stage III non-small cell lung cancer (NSCLC) in patients whose disease has not progressed after chemoradiotherapy, and is the global standard of care in this setting based on the PACIFIC Phase III trial. Imfinzi is also approved in the US, EU, Japan, China and many other countries around the world for the treatment of extensive-stage small cell lung cancer based on the CASPIAN Phase III trial. As part of a broad development programme, Imfinzi is being tested as a single treatment and in combinations with other anti-cancer treatments for patients with small cell lung cancer, NSCLC, bladder cancer, several gastrointestinal cancers, ovarian cancer, endometrial cancer and other solid tumours. Currently, it is in Phase III stage of clinical trial evaluation to treat Locally Advanced Cervical Cancer.

Dostarlimab: GlaxoSmithKlineDostarlimab is a humanised PD-1 monoclonal antibody that binds with high affinity to the PD-1 receptor and blocks its interaction with the ligands PD-L1 and PD-L2. Currently, it is in Phase II stage of clinical trial evaluation to treat Locally Advanced Cervical Cancer.

Andes 1537: Andes BiotechnologiesAndes-1537, a proprietary antisense oligonucleotide designed by Andes Biotechnology, is the Company’s most advanced investigational drug candidate and the first to enter a human clinical study. It targets a novel non-coding mitochondrial RNA (ncmtRNA) and has demonstrated antineoplastic activity in preclinical studies. Upon administration, Andes-1537 binds to a specific ncmtRNA, inducing cell cycle arrest and apoptosis of cancer cells. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Cervical Cancer.

Advanced Cervical Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Advanced Cervical Cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Advanced Cervical Cancer

There are approx. 70+ key companies which are developing the therapies for Advanced Cervical Cancer. The companies which have their Advanced Cervical Cancer drug candidates in the most advanced stage, i.e. phase III include, AstraZeneca.

Phases

This report covers around 75+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Advanced Cervical Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Advanced Cervical Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Advanced Cervical Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Advanced Cervical Cancer drugs.

Advanced Cervical Cancer Report Insights

• Advanced Cervical Cancer Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Advanced Cervical Cancer Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Advanced Cervical Cancer drugs?
• How many Advanced Cervical Cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Advanced Cervical Cancer?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Advanced Cervical Cancer therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Advanced Cervical Cancer and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• AstraZeneca
• GlaxoSmithKline
• Advaxis
• Bristol-Myers Squibb
• Innovent Biologics
• Shanghai Henlius Biotech
• Biocad
• Genexine, Inc.
• Merck KGaA
• Zeria Pharmaceutical
• ISA Pharmaceuticals
• Agenus Inc.
• Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• Vaccibody AS
• Fujifilm Pharmaceuticals U.S.A., Inc.
• NETRIS Pharma
• CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
• Xencor, Inc.
• Sotio a.s.
• Andes Biotechnologies

Key Products

• Durvalumab
• Dostarlimab
• Andes-1537
• ADXS11-001
• SO-C101
• ISA101
• Balstilimab
• XmAb20717
• SG001
• NP137
• FF-10850
• TQ-B3525
• Z-100
• M7824
• VB10.16

This product will be delivered within 1-3 business days.